New results from the POSEIDON study presented at the 94th EAS Congress highlight that cardiovascular inflammation risk persists in 40% of high-risk patients, signaling an urgent need for targeted therapies.
A new subgroup analysis from the Phase 3 VESALIUS-CV trial reveals that Amgen’s Repatha reduces the risk of first major cardiovascular events by 31% in high-risk patients without known atherosclerosis.
Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
